Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response

Cancer Immunology, Immunotherapy

Volumn 64, Issue 6, 2015, Pages 707-716

  Hashimoto, Naoya ^a   Tsuboi, Akihiro ^a   Kagawa, Naoki ^a   Chiba, Yasuyoshi ^a   Izumoto, Shuichi ^c   Kinoshita, Manabu ^a   Kijima, Noriyuki ^a   Oka, Yoshihiro ^a,b   Morimoto, Soyoko ^a   Nakajima, Hiroko ^a   Morita, Satoshi ^d   Sakamoto, Junichi ^e   Nishida, Sumiyuki ^a   Hosen, Naoki ^a   Oji, Yusuke ^a   Arita, Norio ^c   Yoshimine, Toshiki ^a   Sugiyama, Haruo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Tokai Central Hospital of Japan Mutual Aid Association of Public School Teachers   (Japan)

Author keywords

Immunological response; Newly diagnosed glioblastoma; Safe combination; Temozolomide; WT1 peptide vaccination

Indexed keywords

CANCER VACCINE; ISOCITRATE DEHYDROGENASE 1; PEPTIDE VACCINE; TEMOZOLOMIDE; WT1 PROTEIN; ANTINEOPLASTIC AGENT; DACARBAZINE; WT1 PROTEIN, HUMAN;

ADULT; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HYPOKALEMIA; HYPONATREMIA; IMMUNE RESPONSE; INJECTION SITE REACTION; LEUKOPENIA; LONG TERM CARE; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEIZURE; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CANCER VACCINES; COHORT STUDIES; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; WT1 PROTEINS;

EID: 84930416369     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1674-8     Document Type: Article

References (41)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466
2. Yu JS, Liu G, Ying H, Yong WH, Black KL et al (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973–4979
3. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M et al (2005) Clinical evaluation of personalized peptide vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11:4160–4167
4. Terasaki M, Shibui S, Narita Y, Fujimaki T, Aoki T et al (2010) Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 29:337–344
5. Oka Y, Tsuboi A, Elisseeva OA, Udaka K, Sugiyama H (2002) WT1 as a novel target antigen for cancer immunotherapy. Curr Cancer Drug Targets 2:45–54
6. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Tamaki H et al (1999) Constitutive expression of the Wilms’ tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes the proliferation in response to granulocyte-colony stimulation factor (G-CSF). Leuk Res 23:499–505
7. Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H et al (2000) Cancer immunotherapy targeting Wilms’ tumor gene WT1 product. J Immunol 164:1873–1880
8. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323–5337
9. Oji Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka S et al (2004) Overexpression of the Wilms’ tumor gene WT1 in primary astrocytic tumors. Cancer Sci 95:822–827
10. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T et al (2008) Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108:963–971
11. Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE (2002) A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol 4:39–43
12. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V et al (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 95:1155–1160
13. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357–3361
14. Perry JR, Belanger K, Mason WP, Fulton D, Kavan P et al (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28:2051–2057
15. Kong DS, Lee JI, Kim JH, Kim ST, Kim WS et al (2010) Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 12:289–296
16. Abacioglu U, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM et al (2011) Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. J Neuro Oncol 103:585–593
17. Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS et al (2013) Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol 15:242–250
18. Chiba Y, Hashimoto N, Tsuboi A, Oka Y, Murao A et al (2010) Effects of concomitant temozolomide and radiation therapies on WT1-specific T cells in malignant glioma. Jpn J Clin Oncol 40:395–408
19. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
20. Momota S, Narita Y, Miyakita Y, Shibui S (2013) Secondary hematological malignancies associated with temozolomide in patients with glioma. Neuro Oncol 15:1445–1450
21. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T et al (2004) Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 101:13885–13890
22. Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T et al (2002) Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 51:614–620
23. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR (2011) Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acid Res 39:D913–D919
24. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M et al (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9:29–38
25. Li J, Wang M, Won M, Shaw EG, Coughlin C et al (2011) Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 81:623–630
26. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599–601
27. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382
28. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD et al (2004) Selective CD4_ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22:610–616
29. Fujimoto Y, Hashimoto N, Kinoshita M, Miyazaki Y, Tanaka S et al (2012) Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis. Int J Clin Oncol 17:290–293
30. Appay V, Voelter V, Rufer N, Reynard S, Jandus C et al (2007) Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. J Immunother 30:240–250
31. Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L et al (2008) Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol 10:98–103
32. Park SD, Kim CH, Kim CK, Park JA, Sohn HJ et al (2007) Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. Vaccine 25:3485–3491
33. Kim CH, Woo SJ, Park JS, Kim HS, Park MY et al (2007) Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. Immunology 122:615–622
34. Jordan JT, Sun W, Farzana Hussain S, DeAngulo G, Prabhu SS et al (2008) Preferential migration of regulatory T cells mediated by glioma secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 57:123–131
35. Banissi C, Ghiringhelli F, Chen L, Carpentier AF (2009) Treg depletion with a low-dose metronomic temozolomide regimen in rat glioma model. Cancer Immunol Immunother 58:1627–1634
36. Sanchez-Perez LA, Choi BD, Archer GE, Cui X, Flores C et al (2013) Myeloablative temozolomide enhances CD8 T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One 8:e59082
37. North RJ (1982) Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063–1074
38. Dudley ME, Robbins PF, Yang JC, Yang JC, Hwu P et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854
39. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A et al (2011) Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 13:324–333
40. Fadul CE, Fisher JL, Gui J, Hampton TH, Côté AL et al (2011) Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol 13:393–400
41. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722–4729